Rekombinanter CTLA-4 (Ipilimumab Biosimilar) Antikörper

Produktnummer ABIN7200671

Produktdetails anti-CTLA-4 (Ipilimumab Biosimilar) Antikörper

Target: CTLA-4 (Ipilimumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CTLA-4 (Ipilimumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Verwendungszweck: Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody

Spezifität: The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.

Produktmerkmale: Recombinant fully human IgG1 monoclonal antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu CTLA-4 (Ipilimumab Biosimilar)

Target: CTLA-4 (Ipilimumab Biosimilar)

Abstract: CTLA-4 (Ipilimumab Biosimilar) Produkte

Synonyme: CD antikoerper, CD152 antikoerper, CELIAC3 antikoerper, CTLA-4 antikoerper, GRD4 antikoerper, GSE antikoerper, IDDM12 antikoerper, cytotoxic T-lymphocyte associated protein 4 antikoerper, CTLA4 antikoerper

Substanzklasse: Biosimilar

Hintergrund: What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.